Merrimack Pharmaceuticals Company Profile (NASDAQ:MACK)

About Merrimack Pharmaceuticals

Merrimack Pharmaceuticals logoMerrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. Its therapeutic oncology candidates in clinical development include MM-398, MM-302, MM-121, MM-141 and MM-151. Its ONIVYDE (irinotecan liposome injection), also known as MM-398, is an encapsulation of the marketed chemotherapy drug irinotecan in a liposomal formulation. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. MM-121 is a fully human monoclonal antibody that targets Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3). MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes. MM-151 is an oligoclonal therapeutic designed to bind to non-overlapping epitopes of EGFR (ErbB1).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MACK
  • CUSIP: 59032810
Key Metrics:
  • Previous Close: $6.26
  • 50 Day Moving Average: $5.0523
  • 200 Day Moving Average: $6.2720
  • 52-Week Range: $4.39 - $10.85
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.11
  • P/E Growth: -1.0800
  • Market Cap: $822.94M
  • Outstanding Shares: 129,240,000
  • Beta: 2.03
Profitability:
  • Net Margins: -193.54%
  • Return on Assets: -105.60%
Debt:
  • Debt-to-Equity Ratio: -1.07%
  • Current Ratio: 1.31%
  • Quick Ratio: 1.17%
Additional Links:
Companies Related to Merrimack Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Merrimack Pharmaceuticals (NASDAQ:MACK) (?)
Ratings Breakdown: 3 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $11.20 (78.91% upside)

Analysts' Ratings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Show:
DateFirmActionRatingPrice TargetDetails
9/25/2016BTIG ResearchReiterated RatingNeutralView Rating Details
8/10/2016Robert W. BairdReiterated RatingNeutral$8.00 -> $7.00View Rating Details
8/5/2016JPMorgan Chase & Co.Lower Price TargetOverweight$9.00 -> $8.00View Rating Details
8/5/2016Brean CapitalSet Price TargetBuy$16.00 -> $13.00View Rating Details
8/5/2016Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details
5/20/2016MizuhoReiterated RatingBuy$13.00View Rating Details
12/30/2015Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details
8/11/2015Cantor FitzgeraldReiterated RatingBuy$16.00View Rating Details
5/13/2015GuggenheimInitiated CoverageBuy$15.00View Rating Details
(Data available from 9/30/2014 forward)

Earnings

Earnings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/4/2016Q216($0.33)($0.40)$33.35 million$33.70 millionViewN/AView Earnings Details
5/2/2016Q116($0.38)($0.33)$24.16 million$21.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.41)($0.41)$31.73 million$21.42 millionViewListenView Earnings Details
11/9/2015Q315($0.40)($0.38)$14.04 million$16.44 millionViewN/AView Earnings Details
8/10/2015Q215($0.31)($0.21)$17.57 million$36.60 millionViewListenView Earnings Details
5/7/2015($0.30)($0.32)ViewN/AView Earnings Details
2/26/2015Q4($0.23)($0.09)ViewN/AView Earnings Details
11/10/2014($0.12)($0.27)ViewN/AView Earnings Details
8/11/2014($0.32)($0.17)ViewN/AView Earnings Details
5/1/2014Q114($0.30)($0.27)$11.93 million$13.03 millionViewN/AView Earnings Details
2/27/2014($0.29)($0.33)ViewN/AView Earnings Details
11/7/2013($0.34)($0.39)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.28)($0.31)$13.68 million$18.45 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.26)($1.76)$11.77 million$12.58 millionViewN/AView Earnings Details
11/14/2012Q312($1.81)$8.60 million$11.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Merrimack Pharmaceuticals (NASDAQ:MACK)
Current Year EPS Consensus Estimate: $-0.91 EPS
Next Year EPS Consensus Estimate: $-0.88 EPS

Dividends

Dividend History for Merrimack Pharmaceuticals (NASDAQ:MACK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Insider Ownership Percentage: 11.49%
Institutional Ownership Percentage: 66.37%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/25/2016Birgit M SchoeberlInsiderSell50,000$5.50$275,000.00View SEC Filing  
3/17/2016Michael E PorterDirectorBuy5,000$7.20$36,000.00View SEC Filing  
3/15/2016Michael E PorterDirectorBuy5,000$7.65$38,250.00View SEC Filing  
3/8/2016Michael E PorterDirectorBuy10,000$7.09$70,900.00View SEC Filing  
3/3/2016Michael E PorterDirectorBuy15,000$6.39$95,850.00View SEC Filing  
3/1/2016Michael E PorterDirectorBuy20,000$6.11$122,200.00View SEC Filing  
2/29/2016Vivian S LeeDirectorBuy35,000$5.50$192,500.00View SEC Filing  
2/29/2016William M McclementsInsiderBuy2,000$5.72$11,440.00View SEC Filing  
1/5/2016Edward J. StewartinsiderSell4,000$8.00$32,000.00View SEC Filing  
12/1/2015Edward J. StewartinsiderSell5,000$9.33$46,650.00View SEC Filing  
11/2/2015Edward J. StewartinsiderSell6,000$9.42$56,520.00View SEC Filing  
10/16/2015Edward J. StewartinsiderSell1,000$10.00$10,000.00View SEC Filing  
10/2/2015Edward J. StewartinsiderSell5,000$8.20$41,000.00View SEC Filing  
9/1/2015Edward J. StewartinsiderSell6,000$9.88$59,280.00View SEC Filing  
8/21/2015Michael E PorterDirectorBuy5,000$9.76$48,800.00View SEC Filing  
8/17/2015Edward J. StewartinsiderSell6,000$10.49$62,940.00View SEC Filing  
8/14/2015Michael E PorterDirectorBuy13,000$10.54$137,020.00View SEC Filing  
7/20/2015Ulrik B NielsenDirectorSell20,000$10.71$214,200.00View SEC Filing  
7/15/2015Edward J StewartInsiderSell6,000$11.84$71,040.00View SEC Filing  
7/15/2015William A SullivanCFOSell15,000$11.85$177,750.00View SEC Filing  
6/19/2015Ulrik B NielsenDirectorSell40,000$12.02$480,800.00View SEC Filing  
6/18/2015Edward J StewartInsiderSell2,000$12.00$24,000.00View SEC Filing  
6/15/2015Edward J StewartInsiderSell6,000$10.67$64,020.00View SEC Filing  
6/15/2015William A SullivanCFOSell15,000$10.65$159,750.00View SEC Filing  
5/19/2015Ulrik B NielsenDirectorSell40,000$13.04$521,600.00View SEC Filing  
5/13/2015Michael E PorterDirectorBuy8,284$11.79$97,668.36View SEC Filing  
4/20/2015Ulrik B NielsenDirectorSell40,000$12.88$515,200.00View SEC Filing  
4/15/2015Edward J StewartSVPSell8,000$12.79$102,320.00View SEC Filing  
4/15/2015William A SullivanCFOSell15,000$12.87$193,050.00View SEC Filing  
4/13/2015Gordon J FehrDirectorSell20,000$13.00$260,000.00View SEC Filing  
3/24/2015Robert J MulroyCEOSell114,368$11.71$1,339,249.28View SEC Filing  
3/23/2015Robert J MulroyCEOSell10,400$11.69$121,576.00View SEC Filing  
3/20/2015Michael E PorterDirectorBuy5,000$11.77$58,850.00View SEC Filing  
3/19/2015Ulrik B NielsenDirectorSell40,000$11.97$478,800.00View SEC Filing  
3/19/2015William A SullivanCFOSell15,000$11.97$179,550.00View SEC Filing  
3/17/2015Birgit M SchoeberlInsiderSell42,234$12.00$506,808.00View SEC Filing  
3/17/2015Edward J StewartSVPSell8,000$11.95$95,600.00View SEC Filing  
3/17/2015Michael E PorterDirectorBuy1,190$11.77$14,006.30View SEC Filing  
3/16/2015Birgit M SchoeberlInsiderSell20,897$12.00$250,764.00View SEC Filing  
3/16/2015Edward J StewartSVPSell6,000$11.93$71,580.00View SEC Filing  
3/11/2015Michael E PorterDirectorBuy5,000$11.33$56,650.00View SEC Filing  
3/2/2015Michael E PorterDirectorBuy5,000$10.93$54,650.00View SEC Filing  
2/23/2015Ulrik B NielsenDirectorSell20,000$10.91$218,200.00View SEC Filing  
2/20/2015Robert J MulroyCEOSell150,000$10.94$1,641,000.00View SEC Filing  
1/15/2015Edward J StewartSVPSell6,000$11.19$67,140.00View SEC Filing  
12/24/2014William A SullivanCFOSell15,000$10.70$160,500.00View SEC Filing  
12/23/2014Vivian S LeeDirectorBuy20,000$10.23$204,600.00View SEC Filing  
12/18/2014Anthony J SinskeyDirectorSell20,000$10.31$206,200.00View SEC Filing  
12/15/2014Edward J StewartSVPSell6,000$10.63$63,780.00View SEC Filing  
12/8/2014Robert J MulroyCEOSell200,000$9.84$1,968,000.00View SEC Filing  
12/2/2014Michael E PorterDirectorBuy8,000$8.71$69,680.00View SEC Filing  
11/21/2014Michael E PorterDirectorBuy11,909$8.87$105,632.83View SEC Filing  
11/18/2014Edward J StewartSVPSell5,000$8.55$42,750.00View SEC Filing  
11/14/2014Michael E PorterDirectorBuy5,000$8.29$41,450.00View SEC Filing  
11/13/2014Gary L CrockerDirectorBuy14,390$8.47$121,883.30View SEC Filing  
11/12/2014Michael E PorterDirectorBuy40,000$8.37$334,800.00View SEC Filing  
10/23/2014Edward J StewartSVPSell3,000$9.05$27,150.00View SEC Filing  
9/30/2014William A SullivanCFOSell105,282$8.61$906,478.02View SEC Filing  
9/29/2014William A SullivanCFOSell64,404$8.40$540,993.60View SEC Filing  
9/24/2014Edward J StewartSVPSell12,000$8.22$98,640.00View SEC Filing  
6/23/2014Gary L CrockerDirectorBuy36,000$6.84$246,240.00View SEC Filing  
5/20/2014Gary CrockerDirectorBuy4,000$6.69$26,760.00View SEC Filing  
5/19/2014Gary CrockerDirectorBuy9,400$6.68$62,792.00View SEC Filing  
5/16/2014Michael PorterDirectorBuy15,000$6.49$97,350.00View SEC Filing  
5/13/2014Anthony SinskeyDirectorBuy5,000$6.74$33,700.00View SEC Filing  
5/8/2014Michael PorterDirectorBuy10,000$6.59$65,900.00View SEC Filing  
5/7/2014Gary CrockerDirectorBuy4,400$6.77$29,788.00View SEC Filing  
5/6/2014Gary CrockerDirectorBuy17,500$6.89$120,575.00View SEC Filing  
5/5/2014Michael PorterDirectorBuy15,000$6.41$96,150.00View SEC Filing  
5/5/2014Robert MulroyCEOBuy5,000$6.31$31,550.00View SEC Filing  
12/17/2013Michael PorterDirectorBuy25,000$4.75$118,750.00View SEC Filing  
12/12/2013William McclementsSVPBuy4,000$4.26$17,040.00View SEC Filing  
12/10/2013Michael PorterDirectorBuy18,000$4.38$78,840.00View SEC Filing  
12/6/2013James QuigleyDirectorBuy39,000$4.70$183,300.00View SEC Filing  
12/4/2013Robert MulroyCEOBuy33,100$4.42$146,302.00View SEC Filing  
12/3/2013Sarah NashDirectorBuy47,500$4.17$198,075.00View SEC Filing  
12/2/2013William McclementsSVPBuy2,000$4.06$8,120.00View SEC Filing  
11/29/2013Anthony SinskeyDirectorBuy3,800$3.92$14,896.00View SEC Filing  
11/27/2013Gary CrockerDirectorBuy207,000$3.72$770,040.00View SEC Filing  
12/14/2012John MendelsohnDirectorBuy5,000$6.63$33,150.00View SEC Filing  
12/13/2012Gary L CrockerDirectorBuy36,500$6.77$247,105.00View SEC Filing  
12/10/2012Michael E PorterDirectorBuy10,000$6.08$60,800.00View SEC Filing  
9/14/2012Gary L CrockerDirectorBuy64,800$8.33$539,784.00View SEC Filing  
8/24/2012James H QuigleyDirectorBuy12,500$7.55$94,375.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateHeadline
News IconLawrence Page Sells 33332 Shares of Alphabet Inc. (GOOG) Stock (NASDAQ:MACK)
myhealthbowl.com - September 30 at 11:12 AM
streetinsider.com logoMerrimack Pharma (MACK) Will Present Phase 3 NAPOLI-1 Study ... - StreetInsider.com (NASDAQ:MACK)
www.streetinsider.com - September 29 at 5:58 PM
News IconIntraday Active Biotech Stocks News: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), ProNAi Therapeutics, Inc ... - The Voice Registrar (NASDAQ:MACK)
voiceregistrar.com - September 29 at 5:58 PM
News IconIntraday Active Biotech Stocks News: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Incyte Corporation (NASDAQ ... - The Voice Registrar (NASDAQ:MACK)
voiceregistrar.com - September 29 at 5:58 PM
finance.yahoo.com logo4:11 pm Merrimack Pharma will present the final results of the Phase 3 NAPOLI-1 study in a poster at the ESMO Congress (NASDAQ:MACK)
finance.yahoo.com - September 29 at 11:07 AM
capitalcube.com logoETF’s with exposure to Merrimack Pharmaceuticals, Inc. : September 29, 2016 (NASDAQ:MACK)
www.capitalcube.com - September 29 at 11:07 AM
4-traders.com logoMerrimack Pharmaceuticals : to Present Final Results of Phase 3 NAPOLI-1 Study at the European Society for Medical Oncology 2016 Congress (NASDAQ:MACK)
www.4-traders.com - September 28 at 5:50 PM
finance.yahoo.com logoMerrimack to Present Final Results of Phase 3 NAPOLI-1 Study at the European Society for Medical Oncology 2016 Congress (NASDAQ:MACK)
finance.yahoo.com - September 28 at 5:50 PM
News IconArray Biopharma Inc (NASDAQ:ARRY) , Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Are Most Popular Picks At Traders Insights (NASDAQ:MACK)
www.marketnewscall.com - September 28 at 10:57 AM
News IconMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Quarterly Sales Review - Newburgh Press (NASDAQ:MACK)
newburghpress.com - September 27 at 5:56 PM
News IconAnalysts Valuations For Two Stocks: Immune Pharmaceuticals Inc (NASDAQ:IMNP), Merrimack Pharmaceuticals Inc ... - The Voice Registrar (NASDAQ:MACK)
voiceregistrar.com - September 27 at 5:56 PM
News IconHC Trending Hot Stocks! Clovis Oncology Inc (CLVS), Merrimack Pharmaceuticals Inc (NASDAQ:MACK) - share market updates (press release) (NASDAQ:MACK)
sharemarketupdates.com - September 26 at 10:40 AM
News IconBiotech Stocks Worth a Closer Look: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Merrimack Pharmaceuticals ... - The Voice Registrar (NASDAQ:MACK)
voiceregistrar.com - September 26 at 10:40 AM
News IconMerrimack Pharmaceuticals Inc (NASDAQ:MACK) & VimpelCom Ltd (ADR) (NASDAQ:VIP) Stocks in the Spotlight - Money News (NASDAQ:MACK)
www.newsismoney.com - September 26 at 10:40 AM
News IconTradersInsights’ Quickest Trade Of The Week: Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Booked Profit Of 18% in 4 Hours (NASDAQ:MACK)
www.marketnewscall.com - September 25 at 5:23 PM
News IconAchillion Pharmaceuticals Inc. (ACHN) Price Target Raised to $5.00 at Chardan Capital (NASDAQ:MACK)
myhealthbowl.com - September 24 at 5:32 PM
smarteranalyst.com logoBTIG Remains Sidelined on Merrimack Pharmaceuticals Inc (MACK) Despite Encouraging ONIVYDE Script Data for ... - Smarter Analyst (NASDAQ:MACK)
www.smarteranalyst.com - September 23 at 10:43 AM
News IconTime To Put On The Watch List? - Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Anavex Life Sciences Corp ... - The Voice Registrar (NASDAQ:MACK)
voiceregistrar.com - September 23 at 10:43 AM
News IconMerrimack Pharmaceuticals Inc (NASDAQ:MACK): We Bought At $5.32 And Now Up A Whopping 18% In 3 Hours (NASDAQ:MACK)
www.marketnewscall.com - September 22 at 5:46 PM
News IconQuarterly Financial Watch for Merrimack Pharmaceuticals, Inc ... - Newburgh Press (NASDAQ:MACK)
newburghpress.com - September 22 at 10:50 AM
News IconTime To Put On The Watch List? - Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Cerus Corporation (NASDAQ ... - The Voice Registrar (NASDAQ:MACK)
voiceregistrar.com - September 22 at 10:50 AM
News IconTwo Biotechnology Names Are Hot: Merrimack Pharmaceuticals, Inc. (MACK), CoLucid Pharmaceuticals, Inc. (CLCD) - The Independent Republic (NASDAQ:MACK)
theindependentrepublic.com - September 20 at 11:11 AM
News IconIntraday Active Biotech Stocks News: Advaxis (ADXS), Merrimack Pharmaceuticals (MACK) - The Voice Registrar (NASDAQ:MACK)
voiceregistrar.com - September 20 at 11:11 AM
News IconBiotech Stocks Worth a Closer Look: Merrimack Pharmaceuticals ... - The Voice Registrar (NASDAQ:MACK)
voiceregistrar.com - September 16 at 5:50 PM
News IconMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) touched its 52 ... - Newburg Press (NASDAQ:MACK)
newburghpress.com - September 16 at 5:50 PM
News IconNews review of 2 biotech stocks: Merrimack Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:MACK)
voiceregistrar.com - September 16 at 5:50 PM
investopedia.com logoCash Dwindles as Merrimack Fights Cancer (MACK) (NASDAQ:MACK)
www.investopedia.com - September 14 at 10:16 AM
capitalcube.com logoETF’s with exposure to Merrimack Pharmaceuticals, Inc. : September 12, 2016 (NASDAQ:MACK)
www.capitalcube.com - September 12 at 5:49 PM
News IconAnalysts Place Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Under the Lens of the Microscope - Post News (NASDAQ:MACK)
www.kentuckypostnews.com - September 12 at 10:43 AM
fool.com logoWhy Merrimack Pharmaceuticals Inc Fell 20.3% in August -- The ... - Motley Fool (NASDAQ:MACK)
www.fool.com - September 12 at 10:43 AM
fool.com logoWhy Merrimack Pharmaceuticals Inc Fell 20.3% in August (NASDAQ:MACK)
www.fool.com - September 12 at 8:13 AM
News IconWhat is the Sell-side Saying About Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)? - Frisco Fastball (NASDAQ:MACK)
friscofastball.com - September 9 at 5:48 PM
smarteranalyst.com logoBTIG Remains Sidelined on Merrimack Pharmaceuticals Inc (MACK) on Back of Cash Concerns - Smarter Analyst (NASDAQ:MACK)
www.smarteranalyst.com - September 9 at 5:48 PM
News IconBiotech Stocks To Put On Your Watch List: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Amgen Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:MACK)
voiceregistrar.com - September 9 at 5:48 PM
News IconThe Key Numbers To Watch From Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)'s Earnings - The Voice Registrar (NASDAQ:MACK)
voiceregistrar.com - September 9 at 5:48 PM
News IconWorth Watching Stocks to Track: Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Ameren Corp (NYSE:AEE ... - NYSE Journal (press release) (NASDAQ:MACK)
stockznews.com - September 8 at 9:54 AM
News IconHot Biotech Stocks Recap: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), BioMarin Pharmaceutical Inc ... - The Voice Registrar (NASDAQ:MACK)
voiceregistrar.com - September 8 at 9:54 AM
News IconHC Stocks Momentum- Medivation Inc (MDVN), Merrimack Pharmaceuticals Inc (NASDAQ:MACK) - share market updates (press release) (NASDAQ:MACK)
sharemarketupdates.com - September 7 at 9:35 AM
News IconTime To Put On The Watch List? - Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), ZIOPHARM Oncology, Inc ... - The Voice Registrar (NASDAQ:MACK)
voiceregistrar.com - September 2 at 6:04 PM
capitalcube.com logoETF’s with exposure to Merrimack Pharmaceuticals, Inc. : September 2, 2016 (NASDAQ:MACK)
www.capitalcube.com - September 2 at 10:51 AM
News IconStock on Analysts Radar: Merrimack Pharmaceuticals Inc (NASDAQ:MACK) - Post Registrar (NASDAQ:MACK)
postregistrar.com - August 31 at 10:53 AM
prnewswire.com logoBiotech Stocks on Investors' Radar -- Alexion Pharma, BioMarin Pharma, Merrimack Pharma, and Pacific Biosciences ... - PR Newswire (press release) (NASDAQ:MACK)
www.prnewswire.com - August 31 at 10:53 AM
News IconCrowd & Street Analysis on Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - Post News (NASDAQ:MACK)
www.kentuckypostnews.com - August 30 at 9:23 AM
News IconBiotech Stocks To Put On Your Watch List: Mast Therapeutics, Inc. (NYSEMKT:MSTX), Merrimack Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:MACK)
voiceregistrar.com - August 30 at 9:23 AM
News IconUpcoming Earnings Report: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - The Voice Registrar (NASDAQ:MACK)
voiceregistrar.com - August 30 at 9:23 AM
finance.yahoo.com logoWhat Makes Merrimack Pharmaceuticals (MACK) a Strong Sell? (NASDAQ:MACK)
finance.yahoo.com - August 29 at 10:38 AM
News IconBiotech Stocks Worth a Closer Look: Intrexon Corporation (NYSE:XON), Merrimack Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:MACK)
voiceregistrar.com - August 25 at 11:09 AM
News IconActive biotech company shares in the news: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Amicus Therapeutics ... - The Voice Registrar (NASDAQ:MACK)
voiceregistrar.com - August 25 at 11:09 AM
News IconHot Biotech Stocks Recap: Inovio Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:MACK)
voiceregistrar.com - August 24 at 5:54 PM
News IconStock to Watch: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK ... - Newburg Press (NASDAQ:MACK)
newburghpress.com - August 22 at 6:03 PM

Social

Merrimack Pharmaceuticals (NASDAQ:MACK) Chart for Friday, September, 30, 2016


Last Updated on 9/30/2016 by MarketBeat.com Staff